Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies.

Seto NL, Torres-Ruiz JJ, Carmona-Rivera C, Pinal-Fernandez I, Pak K, Purmalek MM, Hosono Y, Fernandes-Cerqueira C, Gowda PC, Arnett N, Gorbach A, Benveniste O, Gómez-Martín D, Selva-O'Callaghan A, Milisenda JC, Grau-Junyent JM, Christopher-Stine L, Miller FW, Lundberg IE, Kahlenberg JM, Schiffenbauer AI, Mammen AL, Rider LG, Kaplan MJ.

JCI Insight. 2020 Jan 16. pii: 134189. doi: 10.1172/jci.insight.134189. [Epub ahead of print]

2.

Routine monitoring of isometric knee extension strength in patients with muscle impairments using a new portable device: cross-validation against a standard isokinetic dynamometer.

Hogrel JY, Benveniste O, Bachasson D.

Physiol Meas. 2020 Jan 14. doi: 10.1088/1361-6579/ab6b49. [Epub ahead of print]

PMID:
31935703
3.

Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients.

Wesner N, Uruha A, Suzuki S, Mariampillai K, Granger B, Champtiaux N, Rigolet A, Schoindre Y, Lejeune S, Guillaume-Jugnot P, Vautier M, Hervier B, Simon A, Granier F, Gallay L, Nishino I, Benveniste O, Allenbach Y.

Autoimmun Rev. 2020 Jan 6:102465. doi: 10.1016/j.autrev.2020.102465. [Epub ahead of print] No abstract available.

PMID:
31918028
4.

Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis.

Dieudonné Y, Allenbach Y, Benveniste O, Leonard-Louis S, Hervier B, Mariampillai K, Nespola B, Lannes B, Echaniz-Laguna A, Wendling D, Von Frenckell C, Poursac N, Mortier E, Lavigne C, Hinschberger O, Magnant J, Gottenberg JE, Geny B, Sibilia J, Meyer A.

Neurology. 2019 Dec 27. pii: 10.1212/WNL.0000000000008863. doi: 10.1212/WNL.0000000000008863. [Epub ahead of print]

PMID:
31882529
5.

239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018.

Mammen AL, Allenbach Y, Stenzel W, Benveniste O; ENMC 239th Workshop Study Group.

Neuromuscul Disord. 2019 Oct 25. pii: S0960-8966(19)31161-7. doi: 10.1016/j.nmd.2019.10.005. [Epub ahead of print] No abstract available.

PMID:
31791867
6.

Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders.

Beigneux Y, Arnulf I, Guillaume-Jugnot P, Leu-Semenescu S, Maillart E, Lubetzki C, Benveniste O, Papeix C.

Mult Scler Relat Disord. 2019 Nov 25;38:101869. doi: 10.1016/j.msard.2019.101869. [Epub ahead of print]

PMID:
31785490
7.

Infliximab as effective treatment for aseptic neutrophilic myositis.

Guillaume-Jugnot P, Guégan S, Léonard-Louis S, Barete S, Benveniste O, Allenbach Y.

Neurology. 2019 Dec 3;93(23):1009-1011. doi: 10.1212/WNL.0000000000008584. Epub 2019 Oct 29. No abstract available.

PMID:
31662493
8.

Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.

Landon-Cardinal O, Benveniste O, Allenbach Y.

Brain. 2019 Nov 1;142(11):e60. doi: 10.1093/brain/awz294. No abstract available.

PMID:
31603183
9.

Inclusion body myositis: accumulation of evidence for its autoimmune origin.

Benveniste O, Allenbach Y.

Brain. 2019 Sep 1;142(9):2549-2551. doi: 10.1093/brain/awz229. No abstract available.

PMID:
31497859
10.

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Auberson LZ, Wu M, de Vera A, Papanicolaou DA, Amato AA; RESILIENT Study Group.

Lancet Neurol. 2019 Sep;18(9):834-844. doi: 10.1016/S1474-4422(19)30200-5.

PMID:
31397289
11.

Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies.

Fischer N, Preuße C, Radke J, Pehl D, Allenbach Y, Schneider U, Feist E, von Casteleyn V, Hahn K, Ruck T, Meuth SG, Goebel HH, Graf R, Mammen A, Benveniste O, Stenzel W.

Brain Pathol. 2019 Aug 3. doi: 10.1111/bpa.12772. [Epub ahead of print]

PMID:
31376301
12.

Response to: 'On using machine learning algorithms to define clinically meaningful patient subgroups' by Pinal-Fernandez and Mammen.

Benveniste O, Allenbach Y, Granger B.

Ann Rheum Dis. 2019 Jul 20. pii: annrheumdis-2019-216007. doi: 10.1136/annrheumdis-2019-216007. [Epub ahead of print] No abstract available.

PMID:
31326897
13.

Biomarkers in Inflammatory Myopathies-An Expanded Definition.

Benveniste O, Goebel HH, Stenzel W.

Front Neurol. 2019 Jun 4;10:554. doi: 10.3389/fneur.2019.00554. eCollection 2019. Review.

14.

Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups.

Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, McHugh NJ, Mammen AL, Betteridge ZE, Tansley SL, Bowes J, Vencovský J, Deakin CT, Dankó K, Vidya L, Selva-O'Callaghan A, Pachman LM, Reed AM, Molberg Ø, Benveniste O, Mathiesen PR, Radstake TRDJ, Doria A, de Bleecker J, Lee AT, Hanna MG, Machado PM, Ollier WE, Gregersen PK, Padyukov L, O'Hanlon TP, Cooper RG, Lundberg IE; Myositis Genetics Consortium (MYOGEN).

Ann Rheum Dis. 2019 Jul;78(7):996-1002. doi: 10.1136/annrheumdis-2019-215046. Epub 2019 May 28.

15.

Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome.

Dzangué-Tchoupou G, Allenbach Y, Preuße C, Stenzel W, Benveniste O.

J Neuroimmunol. 2019 Jul 15;332:212-215. doi: 10.1016/j.jneuroim.2019.04.014. Epub 2019 Apr 29.

PMID:
31082769
16.

PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited.

Knauss S, Preusse C, Allenbach Y, Leonard-Louis S, Touat M, Fischer N, Radbruch H, Mothes R, Matyash V, Böhmerle W, Endres M, Goebel HH, Benveniste O, Stenzel W.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 10;6(3):e558. doi: 10.1212/NXI.0000000000000558. eCollection 2019 May.

17.

Expanding the spectrum of HIV-associated myopathy.

Landon-Cardinal O, Gallay L, Dubourg O, Maisonobe T, Léonard-Louis S, Beniken D, Simon A, Behin A, Stojkovic T, Duyckaerts C, Breton G, Rigolet A, Fain O, Meyohas MC, Leport C, Valantin MA, Vittecoq D, Bergmann JF, Hanslik T, Chauveheid MP, Amoura Z, de Broucker T, Eymard B, Beaudequin N, Benveniste O, Allenbach Y.

J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1296-1298. doi: 10.1136/jnnp-2018-319419. Epub 2019 Apr 11. No abstract available.

PMID:
30975823
18.

Autoantibodies at the Center of (sub)Classification-Issues of Detection-Reply.

Allenbach Y, Mariampillai K, Benveniste O.

JAMA Neurol. 2019 Jul 1;76(7):868-869. doi: 10.1001/jamaneurol.2019.0443. No abstract available.

PMID:
30933238
19.

The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.

Aussy A, Fréret M, Gallay L, Bessis D, Vincent T, Jullien D, Drouot L, Jouen F, Joly P, Marie I, Meyer A, Sibilia J, Bader-Meunier B, Hachulla E, Hamidou M, Huë S, Charuel JL, Fabien N, Viailly PJ, Allenbach Y, Benveniste O, Cordel N, Boyer O; OncoMyositis Study Group.

Arthritis Rheumatol. 2019 Aug;71(8):1360-1370. doi: 10.1002/art.40895. Epub 2019 Jul 8.

PMID:
30896088
20.

Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation.

Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C, Salem JE.

Drug Saf. 2019 Jul;42(7):813-825. doi: 10.1007/s40264-019-00810-9. Review.

PMID:
30868436
21.

Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM).

Huber AT, Lamy J, Bravetti M, Bouazizi K, Bacoyannis T, Roux C, De Cesare A, Rigolet A, Benveniste O, Allenbach Y, Kerneis M, Cluzel P, Redheuil A, Kachenoura N.

Eur Radiol. 2019 Oct;29(10):5139-5147. doi: 10.1007/s00330-019-06054-6. Epub 2019 Mar 7.

PMID:
30847587
22.

Autoantibody testing in idiopathic inflammatory myopathies.

Rietveld A, Lim J, de Visser M, van Engelen B, Pruijn G, Benveniste O, van der Kooi A, Saris C.

Pract Neurol. 2019 Aug;19(4):284-294. doi: 10.1136/practneurol-2017-001742. Epub 2019 Mar 2. Review.

PMID:
30826741
23.

CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis.

Dzangué-Tchoupou G, Mariampillai K, Bolko L, Amelin D, Mauhin W, Corneau A, Blanc C, Allenbach Y, Benveniste O.

Autoimmun Rev. 2019 Apr;18(4):325-333. doi: 10.1016/j.autrev.2019.02.003. Epub 2019 Feb 28. Review.

PMID:
30825520
24.

Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.

Allenbach Y, Bolko L, Toquet S, Landon-Cardinal O, Benveniste O.

Brain. 2019 Mar 1;142(3):e9. doi: 10.1093/brain/awz006. No abstract available.

PMID:
30715158
25.

Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice.

Landon-Cardinal O, Devilliers H, Chavarot N, Mariampillai K, Rigolet A, Hervier B, Allenbach Y, Benveniste O.

J Neuromuscul Dis. 2019;6(1):99-107. doi: 10.3233/JND-180358.

PMID:
30714969
26.

Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy.

Anquetil C, Boyer O, Wesner N, Benveniste O, Allenbach Y.

Autoimmun Rev. 2019 Mar;18(3):223-230. doi: 10.1016/j.autrev.2018.09.008. Epub 2019 Jan 11. Review.

PMID:
30639649
27.

French expert opinion for the management of juvenile dermatomyositis.

Bader-Meunier B, Gitiaux C, Belot A, Brochard K, Mouy R, Ponce D, Bughin V, Jouen F, Musset L, Allenbach Y, Hachulla E, Maillard H, Meyer A, Bourrat E, Benveniste O; French Network of rare autoimmune, autoinflammatory diseases FAI2R.

Arch Pediatr. 2019 Feb;26(2):120-125. doi: 10.1016/j.arcped.2018.12.002. Epub 2019 Jan 10.

PMID:
30638764
28.

Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease.

Mauhin W, Lidove O, Benveniste O.

Orphanet J Rare Dis. 2019 Jan 7;14(1):4. doi: 10.1186/s13023-018-0979-z.

29.

Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy.

Mohassel P, Landon-Cardinal O, Foley AR, Donkervoort S, Pak KS, Wahl C, Shebert RT, Harper A, Fequiere P, Meriggioli M, Toro C, Drachman D, Allenbach Y, Benveniste O, Béhin A, Eymard B, Lafôret P, Stojkovic T, Mammen AL, Bönnemann CG.

Neurol Neuroimmunol Neuroinflamm. 2018 Dec 12;6(1):e523. doi: 10.1212/NXI.0000000000000523. eCollection 2019 Jan.

30.

Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy.

Landon-Cardinal O, Allenbach Y, Soulages A, Rigolet A, Hervier B, Champtiaux N, Monzani Q, Solé G, Benveniste O.

J Rheumatol. 2019 Jun;46(6):623-627. doi: 10.3899/jrheum.171495. Epub 2018 Dec 15.

PMID:
30554155
31.

Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE.

Galeotti C, Stephen-Victor E, Karnam A, Das M, Gilardin L, Maddur MS, Wymann S, Vonarburg C, Chevailler A, Dimitrov JD, Benveniste O, Bruhns P, Kaveri SV, Bayry J.

J Allergy Clin Immunol. 2019 Aug;144(2):524-535.e8. doi: 10.1016/j.jaci.2018.10.064. Epub 2018 Dec 7.

32.

Immune Checkpoint Inhibitor-Associated Myositis.

Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y.

Circulation. 2018 Aug 14;138(7):743-745. doi: 10.1161/CIRCULATIONAHA.118.035898. No abstract available.

PMID:
30359135
33.

Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib.

Allenbach Y, Toquet S, Landon-Cardinal O, Benveniste O.

Brain. 2018 Nov 1;141(11):e81. doi: 10.1093/brain/awy256. No abstract available.

PMID:
30335129
34.

Dermoskeletics to preserve mobility and function in inclusion body myositis.

Landon-Cardinal O, Prince F, Bédard S, Benveniste O, Hudson M.

Neurology. 2018 Oct 16;91(16):760. doi: 10.1212/WNL.0000000000006365. No abstract available.

PMID:
30323070
35.

In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy.

Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G, Jean L, Zoubairi R, Guerout N, Mahler M, Benveniste O, Drouot L, Boyer O.

Ann Rheum Dis. 2019 Jan;78(1):131-139. doi: 10.1136/annrheumdis-2018-213518. Epub 2018 Oct 11.

PMID:
30309969
36.

Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis.

Uruha A, Allenbach Y, Charuel JL, Musset L, Aussy A, Boyer O, Mariampillai K, Landon-Cardinal O, Rasmussen C, Bolko L, Maisonobe T, Leonard-Louis S, Suzuki S, Nishino I, Stenzel W, Benveniste O.

Neuropathol Appl Neurobiol. 2019 Aug;45(5):513-522. doi: 10.1111/nan.12519. Epub 2018 Nov 22.

PMID:
30267437
37.

Peculiar clinicopathological features of immune-mediated necrotizing myopathies.

Allenbach Y, Benveniste O.

Curr Opin Rheumatol. 2018 Nov;30(6):655-663. doi: 10.1097/BOR.0000000000000547. Review.

PMID:
30239349
38.

Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.

Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O.

JAMA Neurol. 2018 Dec 1;75(12):1528-1537. doi: 10.1001/jamaneurol.2018.2598.

39.

Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol.

Lorenzon R, Mariotti-Ferrandiz E, Aheng C, Ribet C, Toumi F, Pitoiset F, Chaara W, Derian N, Johanet C, Drakos I, Harris S, Amselem S, Berenbaum F, Benveniste O, Bodaghi B, Cacoub P, Grateau G, Amouyal C, Hartemann A, Saadoun D, Sellam J, Seksik P, Sokol H, Salem JE, Vicaut E, Six A, Rosenzwajg M, Bernard C, Klatzmann D.

BMJ Open. 2018 Aug 30;8(8):e021037. doi: 10.1136/bmjopen-2017-021037.

40.

Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer.

Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K, Szwebel TA, Kramkimel N, Lethrosne C, Bruch JF, Laly P, Cadranel J, Weiss N, Béhin A, Allenbach Y, Benveniste O, Lenglet T, Psimaras D, Stenzel W, Léonard-Louis S.

Neurology. 2018 Sep 4;91(10):e985-e994. doi: 10.1212/WNL.0000000000006124. Epub 2018 Aug 8. Erratum in: Neurology. 2019 Aug 6;93(6):280.

PMID:
30089619
41.

Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Ladislau L, Arouche-Delaperche L, Allenbach Y, Benveniste O.

Curr Rheumatol Rep. 2018 Aug 3;20(9):56. doi: 10.1007/s11926-018-0763-z. Review.

PMID:
30074107
42.

Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.

Mauhin W, Lidove O, Amelin D, Lamari F, Caillaud C, Mingozzi F, Dzangué-Tchoupou G, Arouche-Delaperche L, Douillard C, Dussol B, Leguy-Seguin V, D'Halluin P, Noel E, Zenone T, Matignon M, Maillot F, Ly KH, Besson G, Willems M, Labombarda F, Masseau A, Lavigne C, Froissart R, Lacombe D, Ziza JM, Hachulla E, Benveniste O.

Orphanet J Rare Dis. 2018 Jul 31;13(1):127. doi: 10.1186/s13023-018-0877-4.

43.

Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.

Landon-Cardinal O, Friedman D, Guiguet M, Laforêt P, Heming N, Salort-Campana E, Jouen F, Allenbach Y, Boyer O, Chatenoud L, Eymard B, Sharshar T, Benveniste O.

J Neuromuscul Dis. 2018;5(2):241-249. doi: 10.3233/JND-180300.

PMID:
29865089
44.

Symptomatic muscular sarcoidosis: Lessons from a nationwide multicenter study.

Cohen Aubart F, Abbara S, Maisonobe T, Cottin V, Papo T, Haroche J, Mathian A, Pha M, Gilardin L, Hervier B, Soussan M, Morlat P, Nunes H, Benveniste O, Amoura Z, Valeyre D.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 16;5(3):e452. doi: 10.1212/NXI.0000000000000452. eCollection 2018 May.

45.

Activated dendritic cells modulate proliferation and differentiation of human myoblasts.

Ladislau L, Portilho DM, Courau T, Solares-Pérez A, Negroni E, Lainé J, Klatzmann D, Bonomo A, Allenbach Y, Benveniste O, Riederer I, Savino W, Mouly V, Butler-Browne G, Benjamim CF.

Cell Death Dis. 2018 May 1;9(5):551. doi: 10.1038/s41419-018-0426-z.

46.

JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.

Ladislau L, Suárez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, Rodero MP, Hathazi D, Duffy D, Bondet V, Preusse C, Bienvenu B, Rozenberg F, Roos A, Benjamim CF, Gallardo E, Illa I, Mouly V, Stenzel W, Butler-Browne G, Benveniste O, Allenbach Y.

Brain. 2018 Jun 1;141(6):1609-1621. doi: 10.1093/brain/awy105.

PMID:
29741608
47.

Muscle Shear Wave Elastography in Inclusion Body Myositis: Feasibility, Reliability and Relationships with Muscle Impairments.

Bachasson D, Dubois GJR, Allenbach Y, Benveniste O, Hogrel JY.

Ultrasound Med Biol. 2018 Jul;44(7):1423-1432. doi: 10.1016/j.ultrasmedbio.2018.03.026. Epub 2018 Apr 26.

48.

Analysis of cell surface and intranuclear markers on non-stimulated human PBMC using mass cytometry.

Dzangué-Tchoupou G, Corneau A, Blanc C, Benveniste O, Allenbach Y.

PLoS One. 2018 Mar 22;13(3):e0194593. doi: 10.1371/journal.pone.0194593. eCollection 2018.

49.

Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis.

Radke J, Koll R, Preuße C, Pehl D, Todorova K, Schönemann C, Allenbach Y, Aronica E, de Visser M, Heppner FL, Weis J, Doostkam S, Maisonobe T, Benveniste O, Goebel HH, Stenzel W.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 6;5(3):e451. doi: 10.1212/NXI.0000000000000451. eCollection 2018 May.

50.

Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping.

Huber AT, Bravetti M, Lamy J, Bacoyannis T, Roux C, de Cesare A, Rigolet A, Benveniste O, Allenbach Y, Kerneis M, Cluzel P, Kachenoura N, Redheuil A.

J Cardiovasc Magn Reson. 2018 Feb 12;20(1):11. doi: 10.1186/s12968-018-0430-6.

Supplemental Content

Loading ...
Support Center